Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

Completed

Conditions studied: COVID-19, Influenza A, Influenza B

In brief

The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users. The COVID/Flu Detect™ Rapid Self-Test is an investigational device intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. Participants who are aged two (2) years and older and have symptoms of respiratory illness consistent with SARS-CoV-2 and influenza infection may be enrolled. Participants will use the COVID/Flu Detect™ Rapid Self-Test to self-collect, self-test, and interpret the results. Participants will have a nasal swab sample collected by a healthcare provider for comparator testing by PCR tests for SARS-CoV-2, influenza A, and influenza B. Researchers will compare the results of the COVID/Flu Detect™ Rapid Self-Test obtained by the participants to results from the PCR comparator tests to evaluate performance.

Key facts

Study ID

NCT06734741

Run by

InBios International, Inc.

People needed

899

Starts

2024-12-26

Expected to finish

2025-05-19

Last updated by the study team

2025-05-22

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must be at least 18 years of age, or at least 2 years of age and accompanied by parent or legal guardian.
• Subjects must be willing and able to give informed consent or assent (as age-appropriate).
• Subjects must be able to read/speak English (or Spanish at specific sites) if subject is an adult, minor aged 14 years or older, or parent/guardian of a child subject aged 2 through 13 years.
• Subjects must be currently exhibiting at least two of the following symptoms consistent with possible SARS-CoV-2 or influenza infection: fever or feeling feverish (in absence of documented fever), chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, nasal congestion or runny nose, nausea or vomiting, and/or diarrhea. Subjects must be within 5 days of symptoms onset at enrollment (the day that symptoms start is day 0).

You may not qualify if…

• Subject was previously enrolled in this study.
• Subject has undergone a nasal wash or nasal aspirate procedure on day of enrollment.
• Subject has an active nosebleed.
• Subject has received results of an influenza or COVID-19 test within the previous 5 days.

Where it is running

• Cahaba Research — Birmingham, Alabama, United States
• Medicus Health Research Group Inc — Miami, Florida, United States
• ASR, LLC — Boise, Idaho, United States
• Barnes-Jewish Hospital — St Louis, Missouri, United States
• St. Louis Children's Hospital — St Louis, Missouri, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Ichan School of Medicine at Mount Sinai, Department of Emergency Medicine — New York, New York, United States
• CHEAR Center LLC. — The Bronx, New York, United States
• Eastside Research Associates — Midland, Texas, United States
• ERA Health Research — Odessa, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.